154 related articles for article (PubMed ID: 14749704)
1. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma.
Ansell SM; Arendt BK; Grote DM; Jelinek DF; Novak AJ; Wellik LE; Remstein ED; Bennett CF; Fielding A
Leukemia; 2004 Mar; 18(3):616-23. PubMed ID: 14749704
[TBL] [Abstract][Full Text] [Related]
2. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
Pagel JM; Laugen C; Bonham L; Hackman RC; Hockenbery DM; Bhatt R; Hollenback D; Carew H; Singer JW; Press OW
Clin Cancer Res; 2005 Jul; 11(13):4857-66. PubMed ID: 16000584
[TBL] [Abstract][Full Text] [Related]
3. Suppression of tumor growth using antisense oligonucleotide against survivin in an orthotopic transplant model of human hepatocellular carcinoma in nude mice.
Sun Y; Lin R; Dai J; Jin D; Wang SQ
Oligonucleotides; 2006; 16(4):365-74. PubMed ID: 17155911
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
5. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively.
Tracey L; Pérez-Rosado A; Artiga MJ; Camacho FI; Rodríguez A; Martínez N; Ruiz-Ballesteros E; Mollejo M; Martinez B; Cuadros M; Garcia JF; Lawler M; Piris MA
J Pathol; 2005 Jun; 206(2):123-34. PubMed ID: 15880597
[TBL] [Abstract][Full Text] [Related]
6. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab.
Ramanarayanan J; Hernandez-Ilizaliturri FJ; Chanan-Khan A; Czuczman MS
Br J Haematol; 2004 Dec; 127(5):519-30. PubMed ID: 15566355
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
8. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
Wang Z; Sampath J; Fukuda S; Pelus LM
Cancer Res; 2005 Sep; 65(18):8224-32. PubMed ID: 16166298
[TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides.
Ma X; Wang S; Zhou J; Xing H; Xu G; Wang B; Chen G; Lu YP; Ma D
Oncol Rep; 2005 Jul; 14(1):275-9. PubMed ID: 15944801
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer.
Ai Z; Yin L; Zhou X; Zhu Y; Zhu D; Yu Y; Feng Y
Cancer; 2006 Aug; 107(4):746-56. PubMed ID: 16826583
[TBL] [Abstract][Full Text] [Related]
11. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs.
Tamm I; Wang Y; Sausville E; Scudiero DA; Vigna N; Oltersdorf T; Reed JC
Cancer Res; 1998 Dec; 58(23):5315-20. PubMed ID: 9850056
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model.
Hernandez-Ilizaliturri FJ; Reddy N; Holkova B; Ottman E; Czuczman MS
Clin Cancer Res; 2005 Aug; 11(16):5984-92. PubMed ID: 16115943
[TBL] [Abstract][Full Text] [Related]
13. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells.
Pennati M; Binda M; Colella G; Zoppe' M; Folini M; Vignati S; Valentini A; Citti L; De Cesare M; Pratesi G; Giacca M; Daidone MG; Zaffaroni N
Oncogene; 2004 Jan; 23(2):386-94. PubMed ID: 14724567
[TBL] [Abstract][Full Text] [Related]
14. Survivin expression in lymph nodes, affected by lymphoma and reactive hyperplasia.
Mazur G; Haloń A; Wróbel T; Urbaniak J; Kuliczkowski K; Woźniak M
Rocz Akad Med Bialymst; 2004; 49 Suppl 1():76-8. PubMed ID: 15638381
[TBL] [Abstract][Full Text] [Related]
15. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
16. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer.
Cao C; Mu Y; Hallahan DE; Lu B
Oncogene; 2004 Sep; 23(42):7047-52. PubMed ID: 15258565
[TBL] [Abstract][Full Text] [Related]
17. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide.
Klasa RJ; Bally MB; Ng R; Goldie JH; Gascoyne RD; Wong FM
Clin Cancer Res; 2000 Jun; 6(6):2492-500. PubMed ID: 10873104
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
19. The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target.
Capalbo G; Rödel C; Stauber RH; Knauer SK; Bache M; Kappler M; Rödel F
Strahlenther Onkol; 2007 Nov; 183(11):593-9. PubMed ID: 17960333
[TBL] [Abstract][Full Text] [Related]
20. Survivin multifaceted activity in head and neck carcinoma: current evidence and future therapeutic challenges.
Marioni G; D'Alessandro E; Bertolin A; Staffieri A
Acta Otolaryngol; 2010; 130(1):4-9. PubMed ID: 19322702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
